Composition for use in treatment and / or prevention of chronic kidney disease complications, kidney disorder progression inhibitor, sarcopenia progression inhibitor, and anemia progression inhibitor
Lactoferrin-based compositions address the ineffectiveness of existing treatments for chronic kidney disease by inhibiting renal damage and anemia, and improving muscle health, effectively managing chronic kidney disease progression in adenine-induced models.
Patent Information
- Application Number
- PCT/JP2024/017376
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Current compositions and treatments are ineffective in addressing the progression of chronic kidney disease complications, particularly in inhibiting renal damage, sarcopenia, and anemia, as existing models for acute kidney injury do not translate to chronic kidney disease mechanisms.
A composition containing lactoferrin as an active ingredient is developed to treat and prevent chronic kidney disease complications by inhibiting renal damage, sarcopenia, and anemia, using an adenine-induced renal failure model that directly progresses to chronic kidney disease, rather than acute kidney injury.
Lactoferrin effectively suppresses renal atrophy, inflammation, fibrosis, and uremic toxin accumulation, while improving muscle fascicle cross-section and hemoglobin levels, thereby preventing the progression of chronic kidney disease complications.
Smart Images

Figure JP2024017376_21112024_PF_FP_ABST
Abstract
Description
Composition for use in the treatment and / or prevention of complications of chronic kidney disease, agent for inhibiting the progression of kidney damage, agent for inhibiting the progression of sarcopenia, and agent for inhibiting the progression of anemia
[0001] The disclosure in the present application relates to a composition for use in the treatment and / or prevention of complications of chronic kidney disease, an agent for inhibiting the progression of kidney damage, an agent for inhibiting the progression of sarcopenia, and an agent for inhibiting the progression of anemia.
[0002] The kidneys are organs that excrete waste products from the blood, balance the body's water and its content, regulate the acidity and alkalinity of the blood, secrete hematopoietic hormones, regulate blood pressure, and activate vitamin D involved in calcium metabolism. Renal failure is known as a pathological condition of the kidney. Renal failure refers to a state of renal dysfunction centered on a decrease in glomerular filtration rate (GFR). Renal failure is broadly classified into acute renal failure (ARF) and chronic renal failure (CRF) depending on the progression of the renal failure state. Chronic kidney disease (CKD) is a concept that identifies renal dysfunction as a disease at an earlier stage before it reaches CRF, while acute kidney injury (AKI) is a concept that includes renal dysfunction at an earlier stage in order to improve the prognosis of ARF.
[0003] Acute kidney injury is a condition in which a rapid decline in renal function over a period of hours to weeks leads to a breakdown in the homeostasis of bodily fluids, resulting in azotemia, water and electrolyte abnormalities, and acid-base imbalance. Acute kidney injury is defined as a state in which functional or structural changes occur in the kidney due to damage caused by various causes, resulting in rapid (within 48 hours) renal dysfunction.
[0004] On the other hand, chronic kidney disease is defined as a condition in which there is a decline in renal function as indicated by glomerular filtration rate (GFR) or findings suggesting renal damage persist chronically.
[0005] Acute kidney injury is also known to progress to chronic kidney disease. The progression of acute kidney injury to chronic kidney disease is known to occur in the following ways: (1) after the onset of acute kidney injury, the patient progresses to end-stage renal failure (ESRD) and transitions to maintenance dialysis, (2) the patient progresses to chronic kidney disease due to incomplete recovery of renal function, and (3) the patient's renal function temporarily recovers to its pre-treatment level after the onset of acute kidney injury, but then progresses to chronic kidney disease.
[0006] A decline in renal function leads to a decline in quality of life, such as the need for dialysis or kidney transplantation, and an increased risk of developing other diseases. Therefore, there is a need for drugs that can treat or prevent the progression of renal failure.
[0007] Non-Patent Document 1 describes that lactoferrin restored renal function and inhibited renal fibrosis in a mouse model in which acute kidney injury progressed to chronic kidney disease.
[0008] Yung-Ho Hsu et. al. , “Lactoferrin Contributes a Renoprotective Effect in Acute Kidney Injury and Early Renal Fibrosis”, Pharmaceuticals 2020,12,434
[0009] Chronic kidney disease can lead to complications due to the prolonged state of impaired renal function. However, since the mechanisms of onset of acute kidney injury and chronic kidney disease are different, there is a problem that the model mice that develop acute kidney injury described in Non-Patent Document 1 cannot be used to develop compositions for use in treating and / or preventing complications of chronic kidney disease.
[0010] The present invention has been disclosed to solve the above-mentioned problems. As a result of extensive research, the present inventors have newly discovered that lactoferrin can be used to treat and / or prevent complications of chronic kidney disease by using a mouse model of adenine-induced renal failure.
[0011] That is, an object of the disclosure of the present application is to provide a composition for use in the treatment and / or prevention of complications of chronic kidney disease, an agent for inhibiting the progression of kidney damage, an agent for inhibiting the progression of sarcopenia, and an agent for inhibiting the progression of anemia.
[0012] (1) A composition for use in the treatment and / or prevention of complications of chronic kidney disease, comprising lactoferrin as an active ingredient. (2) The composition according to (1), wherein the treatment and / or prevention of complications of chronic kidney disease is the suppression of the progression of sarcopenia and / or anemia by suppressing the progression of renal damage in chronic kidney disease. (3) The composition according to (2), wherein the suppression of the progression of renal damage is the suppression of the progression of at least one selected from the group consisting of renal atrophy, tubulointerstitial damage, and decreased renal function. (4) The composition according to (2), wherein the suppression of the progression of renal damage is the suppression of inflammation and / or fibrosis in the kidney. (5) The composition according to (2), wherein the suppression of the progression of sarcopenia is the suppression of the reduction of muscle bundle cross-sectional area and / or the reduction of uremic toxin accumulation in muscle. (6) An agent for suppressing the progression of renal damage in chronic kidney disease, comprising lactoferrin as an active ingredient. (7) An agent for suppressing the progression of sarcopenia in chronic kidney disease, comprising lactoferrin as an active ingredient. (8) An agent for suppressing the progression of anemia in chronic kidney disease, comprising lactoferrin as an active ingredient. (9) The composition according to any one of (1) to (5) above, which is used as an ingredient of a food composition or a pharmaceutical composition. (10) The agent for suppressing the progression of anemia according to any one of (6) to (8) above, which is used as an ingredient of a food composition or a pharmaceutical composition.
[0013] The compositions for use in the treatment and / or prevention of complications of chronic kidney disease, the agents for inhibiting the progression of nephropathy, the agents for inhibiting the progression of sarcopenia, and the agents for inhibiting the progression of anemia disclosed in the present application can prevent or inhibit the progression of nephropathy, sarcopenia, and anemia, which are complications of chronic kidney disease.
[0014] Figure 1A is a graph showing changes in water intake in the adenine-administered group, lactoferrin-administered group (adenine + Lf-administered group), and control group in an experiment using mice without renal failure. Figure 1B is a graph showing changes in body weight in each group. Figure 2 is a photograph of the kidneys removed at autopsy for each group and a graph of kidney weight / body weight. Figure 3 is a graph showing changes in blood urea nitrogen (BUN) in each group. Figure 4 is a graph showing the results of measuring blood creatinine concentrations in each group. Figure 5 is a graph showing the concentrations of indoxyl sulfate, hippuric acid, and p-cresyl sulfate in the blood of each group. Figure 6 is a photograph of Masson trichrome-stained kidneys for each group and a graph showing the percentage of remaining tubules. Figure 7 is a photograph of HE-stained kidneys for each group and a graph showing the percentage of crystals. Figure 8 is a graph showing the F4 / 80 positivity rate for each group. Figure 9 is a graph showing the changes in hemoglobin and hematocrit in blood collected from the buccal vein of each group. Figure 10 is a photograph of HE-stained left thigh muscles of each group and a graph showing muscle bundle cross-sectional area. Figure 11 is a graph showing the concentrations of indoxyl sulfate and hippuric acid in the muscles of each group. Figure 12 is a graph showing the gene expression of p47phox, an indicator of oxidative stress in the kidneys of each group. Figure 13 is a graph showing the kidney weight / body weight and heart weight / body weight extracted at autopsy for the lactoferrin-untreated group (Adenine), the lactoferrin-treated group (Adenine + Lf), and the control group (Control) in an experiment using mice with renal failure. Figure 14 is a graph showing the concentration of indoxyl sulfate in the blood of each group. Figure 15 is a graph showing the results of enrichment analysis using MetaboAnalyst 5.0. Figure 16 is a graph comparing the amounts of valine, leucine, and isoleucine in the quadriceps muscle among the three groups. Figure 17 is a graph comparing the phosphorylation ratios among the three groups, where the amount of phosphorylated p70S6K relative to the expression level of p70S6K was quantified by quantifying the band density, with the control set at 1.Figure 18 shows the results of Western blotting of LC3 in quadriceps muscle, and a graph comparing the expression levels among the three groups by quantifying the intensity of the LC3-II band and correcting it with β-actin, with the control set to 1. Figure 19 shows the results of Western blotting of Cathepsin B in quadriceps muscle, and a graph comparing the expression levels among the three groups by quantifying the intensity of the Cathepsin B band and correcting it with β-actin, with the control set to 1. Figure 20 shows the results of Western blotting of AMPKα and phosphorylated AMPKα in quadriceps muscle, and a graph comparing the phosphorylation rate among the three groups by quantifying the intensity of the band and quantifying the amount of phosphorylated AMPKα relative to the expression level of AMPKα, with the control set to 1. Figure 21 is an explanatory diagram of the experimental schedule for the therapeutic effect of Lf on chronic kidney disease using C57BL / 6JJcl males. Figure 22 shows representative Elastica-Masson-stained kidney pathology photographs and a graph comparing the quantification of the remaining tubule rate among the three groups. Figure 23 shows a graph comparing the expression levels of fibrosis-related genes in the kidney among the three groups. Figure 24 shows representative H&E-stained quadriceps muscle cross-section photographs, a graph comparing the quantification of muscle bundle cross-sectional areas among the three groups, and a distribution diagram of muscle bundle cross-sectional areas. Figure 25 shows a graph comparing the indoxyl sulfate concentration in the quadriceps muscle among the three groups.
[0015] The compositions for use in the treatment and / or prevention of complications of chronic kidney disease, the agents for inhibiting the progression of nephropathy, the agents for inhibiting the progression of sarcopenia, and the agents for inhibiting the progression of anemia disclosed in the present application are described in detail below. Note that in this specification, numerical values, numerical ranges, and qualitative expressions (e.g., expressions such as "same" and "the same") indicate numerical values, numerical ranges, and properties that include errors generally accepted in the technical field.
[0016] (Embodiments of a composition, a renal damage progression inhibitor, a sarcopenia progression inhibitor, and an anemia progression inhibitor for use in the treatment and / or prevention of chronic kidney disease complications) A composition, a renal damage progression inhibitor, a sarcopenia progression inhibitor, and an anemia progression inhibitor for use in the treatment and / or prevention of chronic kidney disease complications (hereinafter, common features of the composition and the progression inhibitor may be referred to as the "composition / inhibitor") contain lactoferrin as an active ingredient. In this specification, "treatment" means alleviating the symptoms or inhibiting the progression of chronic kidney disease complications that have developed. Furthermore, "prevention" means preventing or delaying the onset of chronic kidney disease complications, or inhibiting the onset and progression of the complications.
[0017] Lactoferrin is an iron-binding glycoprotein found in the milk, tears, saliva, blood, etc. of mammals, such as sheep, goats, pigs, mice, buffalo, camels, yaks, horses, donkeys, llamas, cattle, and humans. The lactoferrin contained in the composition / inhibitor according to the embodiment can be derived from any of the mammals listed above or any other mammals not listed above. From the viewpoints of content and availability, rather than technical aspects, lactoferrin derived from milk of cows, humans, etc., is preferred. Examples of milk include colostrum, transitional milk, normal milk, and terminal milk.
[0018] Lactoferrin may be lactoferrin separated by conventional methods (e.g., ion chromatography) from processed milk products such as skim milk or whey, recombinant lactoferrin produced by genetic engineering from microorganisms, animal cells, transgenic animals, or synthetic lactoferrin, or a mixture thereof. Lactoferrin may also be non-glycosylated or glycosylated. Commercially available lactoferrin produced on an industrial scale can be used as such lactoferrin.
[0019] The metal content in lactoferrin is not particularly limited, and any one or a mixture of two or more selected from the group consisting of apo-lactoferrin obtained by de-ironizing lactoferrin with hydrochloric acid, citric acid, etc.; metal-saturated lactoferrin with a saturation level of 100% or more obtained by chelating the apo-lactoferrin with metals such as iron, copper, zinc, manganese, etc.; and partially metal-saturated lactoferrin in which metals are bound at various levels of saturation less than 100% can be used.
[0020] A non-limiting example of a method for preparing lactoferrin (separating and purifying lactoferrin from raw materials such as milk) is as follows: A milk raw material is passed through a cation exchange column, the permeate is collected, and the permeate is passed through the column repeatedly as needed. Deionized water and saline are passed through the column to obtain an eluate of basic proteins adsorbed to the cation exchange column. This eluate is recovered by ammonium sulfate precipitation and washed as needed. The recovered precipitate is dissolved in deionized water, and the resulting solution is filtered through an ultrafiltration membrane. Powdered lactoferrin is obtained by further desalting and lyophilization. Of course, commercially available, prepared lactoferrin may also be used.
[0021] Depending on the species, genus, individual, etc., lactoferrin may have genetic mutations such as substitution, deletion, insertion, addition, or inversion of one or more bases at one or more positions. Furthermore, mutations may also occur in the amino acids of the protein encoded by the gene having such mutations. The lactoferrin contained in the composition / inhibitor according to the embodiment may contain such mutations, as long as the effects of the composition / inhibitor are achieved. Furthermore, as long as the effects of the composition / inhibitor are achieved, the lactoferrin may be a lactoferrin-treated product that has been subjected to heat treatment, acid treatment, or alkali treatment, or may contain a portion of such a treated lactoferrin.
[0022] Dosage forms of the compositions and inhibitors according to the embodiments include, for example, tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments, soft and hard gelatin capsules, suppositories, eye drops, nasal drops, patches, sterile injectable solutions, and sterile sealed powders.
[0023] The compositions and inhibitors according to the embodiments may also contain carriers, excipients, and diluents. Examples include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, phosphate-buffered saline (PBS), syrup, methylcellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil. Furthermore, lubricants, wetting agents, emulsifiers and suspending agents, preservatives, sweeteners, or flavoring agents may also be added. Furthermore, when the compositions and inhibitors according to the embodiments are administered by injection, they may be combined with known agents such as water-soluble hyaluronic acid, steroids, anesthetics, and anti-inflammatory agents, depending on the injection site.
[0024] The dosage of the composition / inhibitor according to the embodiment may be appropriately determined depending on the purpose. Incidentally, the Clinical Lactoferrin Research Society website (http: / / www.clinical-lactoferrin.com / ) describes that lactoferrin should be administered at a dose of 100 mg to 1,200 mg per day, although this varies depending on the disease. While not limiting, the amount of lactoferrin contained in the composition / inhibitor may be determined based on this description so that a human can ingest approximately 100 mg to 1,200 mg per day.
[0025] The compositions and inhibitors according to the embodiments can be used as ingredients in pharmaceutical compositions or food compositions.
[0026] First, the case where the composition and inhibitor according to the embodiment are used as ingredients in a food composition will be described. As long as the composition and inhibitor according to the embodiment are included as ingredients in the food composition, there are no particular limitations on the other ingredients in the food composition. Food compositions containing the composition and inhibitor according to the embodiment can be provided as functional foods, such as foods for specified health uses, that have efficacy such as preventing complications of chronic kidney disease, inhibiting the progression of nephropathy in chronic kidney disease, inhibiting the progression of sarcopenia in chronic kidney disease, and inhibiting the progression of anemia in chronic kidney disease. The intake amount required to achieve such efficacy can be appropriately determined, taking into account that foods, such as functional foods, are taken daily, continuously, or intermittently over a long period of time.
[0027] Although not limited thereto, the amount of lactoferrin contained in the food composition may be set so that, as with the above-mentioned compositions and inhibitors, a human can ingest approximately 100 mg to 1,200 mg per day. The intake period of the food composition is not particularly limited, but from the viewpoint of prevention or progression inhibition, it is preferable to take it for a long period of time. Examples of such intake periods include, but are not limited to, one week or more, two weeks or more, three weeks or more, one month or more, three months or more, six months or more, and one year or more.
[0028] Food compositions (included in drinking water food compositions) can be in any form of solid, gel, or liquid. Examples include fermented dairy products such as lactic acid bacteria drinks, various processed foods and beverages, dry powders, tablets, capsules, granules, and the like, as well as various beverages, yogurt, liquid foods, jellies, candies, retort pouch foods, tablet confections, cookies, castella cakes, bread, biscuits, chocolate, and the like. Furthermore, additives such as sugars, proteins, lipids, vitamins, minerals, flavors, carbohydrates, sweeteners, fragrances, colorants, texture improvers, and the like, or mixtures thereof, may be added to the food compositions to improve nutritional balance, flavor, and the like.
[0029] Next, a case where the composition / inhibitor according to the embodiment is used as an ingredient of a pharmaceutical composition will be described. As long as the composition / inhibitor according to the embodiment is included as an ingredient of the pharmaceutical composition, there are no particular limitations on the other ingredients of the pharmaceutical composition. A pharmaceutical composition containing the composition / inhibitor according to the embodiment can be provided as a pharmaceutical composition having efficacy such as prevention of chronic kidney disease complications, suppression of the progression of nephropathy in chronic kidney disease, suppression of the progression of sarcopenia in chronic kidney disease, or suppression of the progression of anemia in chronic kidney disease, or as a pharmaceutical composition with added efficacy.
[0030] The pharmaceutical composition can be administered locally or systemically. The administration route is not particularly limited, and may be either oral or parenteral (e.g., ophthalmic or nasal). In addition, the pharmaceutical composition may contain, in addition to the active ingredient lactoferrin, a pharmacologically acceptable carrier depending on the administration route. Examples of the carrier include excipients, disintegrants or disintegration aids, binders, lubricants, coating agents, pigments, diluents, bases, solubilizers or solubilizers, isotonicity agents, pH adjusters, stabilizers, propellants, and adhesives.
[0031] The dosage of the pharmaceutical composition varies depending on the patient's weight, age, etc., and is not particularly limited. The dosage can be set appropriately by a physician. As with food compositions, the amount of lactoferrin contained in the pharmaceutical composition may be set so that a human can be administered approximately 100 mg to 1,200 mg per day, as a rough guideline.
[0032] Chronic kidney disease is not limited to humans, but can also occur in non-human animals such as dogs, cats, horses, and birds. The composition and inhibitor disclosed in the present application can also be used in non-human animals. The dosage can be adjusted appropriately depending on the body weight, etc.
[0033] Complications of chronic kidney disease include impaired urinary concentration, azotemia, water / electrolyte abnormalities (fluid overload, hyperkalemia), metabolic acidosis, secondary hyperparathyroidism, as well as renal anemia caused by kidney damage, and sarcopenia (muscle atrophy), bone damage, cognitive impairment, etc., which are caused by uremic toxins that accumulate in the body due to decreased kidney function. The compositions and inhibitors according to the embodiments treat and prevent or suppress the progression of these complications.
[0034] More specific examples of inhibiting the progression of renal damage include inhibiting the progression of renal atrophy, tubulointerstitial damage, and decreased renal function. Also included is inhibiting the progression of inflammation and / or fibrosis in the kidney. Renal atrophy, as used herein, refers to a state in which the kidneys have shrunk to nearly half their normal size and are dysfunctional. Tubulointerstitial damage refers to damage to the interstitium, the tissue between the renal tubules (tissues that reabsorb essential components of the body, such as water and electrolytes in urine excreted from the glomerulus, and return them to the blood, while excreting unnecessary components as urine). Renal function decline refers to a condition in which the glomerular filtration rate is 60 ml / min / 1.73 m 2 Kidney inflammation refers to the progression of renal inflammation to less than 100%. Kidney inflammation is caused by immunological mechanisms, such as immune responses to infections and various allergic reactions to drugs, which result in the infiltration of inflammatory cells, such as macrophages and lymphocytes, into the interstitium, and the activated macrophages produce and induce inflammatory cytokines. Kidney fibrosis refers to the fibrosis of the interstitial area.
[0035] Sarcopenia (muscle atrophy) refers to a condition characterized by a decrease in muscle mass and strength, more specifically, a decrease in muscle cross-section and / or the accumulation of uremic toxins in the muscle.
[0036] Anemia is caused by a decrease in the hemopoietin (erythropoietin) produced by the kidneys, and is characterized by low hemoglobin and hematocrit levels, palpitations, shortness of breath, dizziness, etc.
[0037] Next, the differences between the adenine-induced renal failure model mouse used in the examples of the present application and the model mouse described in Non-Patent Document 1 will be explained.
[0038] The adenine-induced renal failure model mouse used in the examples of the present application is a mouse model in which administration of adenine causes gradual crystallization of 2,8-dihydroxyadenine (2,8-DHA), an adenine metabolite, in the renal tubules, resulting in persistent inflammation and cytokine production by monocytes and macrophages, leading to fibrotic tubulointerstitial nephritis, resulting in the progression of renal damage. The adenine-induced renal failure model mouse does not progress to the acute kidney injury (AKI) phase, but directly progresses to the pathological condition of chronic kidney disease (CKD). Therefore, this model is not suitable for inducing acute kidney injury.
[0039] On the other hand, Non-Patent Document 1 uses a mouse model in which folic acid-induced acute kidney injury progresses to chronic kidney disease. In the mouse model in Non-Patent Document 1, acute tubular necrosis (disappearance of the brush border of the proximal tubule, vacuolation, detachment, coagulation necrosis, etc.) due to rapid crystal formation occurs after high-dose folic acid administration, and then tubular necrosis does not recover, leading to tubular atrophy and interstitial fibrosis, leading to progression to chronic kidney disease.
[0040] As described above, the mechanisms by which renal failure develops are completely different between the mice used in the present application and the mice described in Non-Patent Document 1. As will be shown in the Examples below, it has been shown that lactoferrin exerts completely different mechanisms of action in the mice used in the present application and the mice described in Non-Patent Document 1.
[0041] In addition to the model mouse described in Non-Patent Document 1, spontaneous type 2 diabetes model mice are also known that develop kidney damage (mainly glomerular damage) caused by diabetes-associated hyperglycemia. Spontaneous type 2 diabetes model mice are mice that develop proteinuria and kidney dysfunction due to glomerular damage (mesangial cell proliferation, inflammatory cell infiltration into glomeruli, glomerular capillary wall damage, etc.). The mechanism of pathological development of the spontaneous type 2 diabetes model mouse is different from that of the model mouse used in the present application.
[0042] The treatment goals and methods differ between acute and chronic renal failure. While renal dysfunction in acute renal failure is expected to be reversible, chronic renal failure is irreversible. Therefore, treatment for acute renal failure aims to restore renal function, while treatment for chronic renal failure aims to slow the progression of renal dysfunction. More specifically, acute renal failure involves drug therapy to eliminate the cause and symptomatic treatment until renal function is restored. Meanwhile, chronic renal failure involves drug therapy to manage risk factors such as hypertension and diabetes, and symptomatic treatment to maintain quality of life. For example, medications to improve long-term abnormalities (e.g., anemia, bone metabolism disorders) are only needed in chronic renal failure.
[0043] As described above, acute renal failure and chronic renal failure have different pathological mechanisms, and their treatment objectives and methods are also different. Therefore, when screening for drugs for treating, preventing, or suppressing the progression of renal failure, it is necessary to select an appropriate model mouse according to the purpose, not only whether the target is acute renal failure or chronic renal failure, but also the mechanism by which renal failure develops. The disclosure of the present application is a new discovery that lactoferrin treats and / or prevents chronic kidney disease complications using an adenine-induced renal failure model mouse from the perspective of treating and / or preventing chronic kidney disease complications.
[0044] The following examples are provided to specifically explain the embodiments disclosed in the present application, but these examples are merely for the purpose of explaining the embodiments and are not intended to limit or restrict the scope of the invention disclosed in the present application.
[0045] [Experimental animals and experimental procedures: Confirmation of preventive effect on chronic kidney disease complications] <Experimental animals> Mice: 7-week-old C57BL / 6JJcl male mice (purchased from CLEA Japan, Inc. and bred for 1 week for acclimation) were used. <Experimental procedures> 8-week-old mice were randomly divided into three groups: a renal failure group (Adenine administration group), a lactoferrin administration group (Adenine + Lf administration group), and a control group (Control group) (n = 6 in each group).
[0046] The renal failure group was fed an adenine diet (MF) (Oriental Yeast Co., Ltd.) containing 0.2% adenine (A8626, Merck, New Jersey, USA) for 6 weeks. The 0.2% adenine-containing MF diet was prepared by Oriental Yeast. The rats were given tap water ad libitum.
[0047] The control group was fed a control MF diet containing no adenine for 6 weeks, and was given tap water ad libitum.
[0048] The lactoferrin administration group, like the renal failure group, was given MF (Oriental Yeast Co., Ltd.) (adenine diet) containing 0.2% adenine (A8626, Merck, New Jersey, USA) for 6 weeks.The lactoferrin administration group was given 2% lactoferrin aqueous solution ad libitum instead of tap water.The lactoferrin aqueous solution was prepared by completely dissolving 10g of Australian Lf (NRL Pharma Co., Ltd.) in 500mL of tap water, and then adjusted to 2%.
[0049] After 6 weeks, the mice were euthanized under isoflurane anesthesia, blood was collected, and kidney and muscle samples were collected after whole-body perfusion with 0.9% saline.
[0050] [Regarding the suppression of weight loss caused by adenine administration by lactoferrin] Figure 1 is a graph showing the change in water intake and body weight for each group. As shown in Figure 1A, the administration of adenine increased water intake. As shown in Figure 1B, compared with the control group, the adenine-administered group experienced a weight loss, but the administration of lactoferrin suppressed weight loss in the lactoferrin-administered group.
[0051] [Lactoferrin inhibits adenine-induced renal atrophy] Figure 2 shows a photograph of the kidneys removed at autopsy and a graph of kidney weight / body weight. As is clear from Figure 2, it was confirmed that lactoferrin inhibits adenine-induced renal atrophy.
[0052] [Lactoferrin suppresses adenine-induced decline in renal function and suppresses an increase in blood uremic toxins] <Quantification of blood urea nitrogen (BUN)> For the measurement of urea nitrogen, mouse plasma was diluted 20-fold or 200-fold with ultrapure water. BUN colorimetric kit (Arbor Assays, NN Arbor, NC, USA) was used and measured according to the instruction manual as follows.
[0053] The treatment was carried out according to the manual in a 96-well transparent plate (1-1601-02; AS ONE Corporation). After incubation at room temperature for 30 minutes, the absorbance at 450 nm was measured using a Spectra Max 190 (Molecular Devices, San Jose, CA, USA). A calibration curve was created using four-parameter logistic regression analysis, and the urea nitrogen concentration was calculated from the measured absorbance.
[0054] The results are shown in Figure 3. As is clear from Figure 3, in the lactoferrin administration group, blood urea nitrogen was suppressed by the administration of lactoferrin.
[0055] <Measurement of plasma creatinine and uremic toxins> 50 μL of mouse plasma was diluted with 0.1% formic acid methanol (1.25 μg / mL 3-indoxyl sulfate-d 4 , 1 μg / mL Creatinine-d 3 150 μL of a solution containing 1,000 μL of HCl was added and mixed by vortexing. Then, the mixture was sonicated for 5 minutes, centrifuged at 16,400 × g for 20 minutes at 4°C, and the resulting supernatant was filtered through a 0.2 μm filter (YMC Duo-Filter, YMC, Kyoto, Japan).
[0056] The concentration of IS (indoxylic acid) was measured by liquid chromatography tandem mass spectrometry (LC-MS / MS). The LC section was a NANOSPACE S1-2 (Shiseido, Tokyo, Japan), and the MS section was a TSQ Quantum Ultra (Thermo Fisher Scientific, San Jose, CA, USA). Measurements were performed in negative mode using a 150 x 2.0 mm YMC-Pack Pro C18 column (#AS12S03-1502WT; YMC, Kyoto, Japan). The mobile phase consisted of 10 mM ammonium acetate (solvent A) and acetonitrile (solvent B). The flow rate was 0.3 mL / min, with the following gradient:
[0057] 0-3 min: 0-50% solvent B; 3.1-4 min: 50-80% solvent B; 4.1-5 min: 80-100% solvent B; 5.1-7 min: 100% solvent B; 7.1-10 min: 0% solvent B.
[0058] IS and IS-d 4 The analysis was performed by SRM (selected reaction monitoring), with the parent ion m / z 212 and the product ion m / z 80 in IS, collision energy 21 V, T-Lens 112 V, and IS-d 4 The parent ion was m / z 216 and the product ion was m / z 80, and the detection was performed at a collision energy of 30V.
[0059] Hippuric acid has a parent ion m / z 178 and a product ion m / z 134, collision energy 13V, T-Lens 71V, Hippuric acid-d 5 The parent ion was m / z 183 and the product ion was m / z 139, and the detection was performed with a collision energy of 27 V and a T-Lens of 71 V.
[0060] For p-cresyl sulfate, the parent ion was m / z 187 and the product ion was m / z 107. The collision energy was 23 V, the T-Lens was 44 V, and the p-cresyl sulfate-d 4The parent ion was m / z 191 and the product ion was m / z 110, and the detection was performed with a collision energy of 30 V and a T-Lens of 44 V. The spray voltage, vaporizer temperature, and capillary temperature were set to 2,500 V, 450° C., and 220° C., respectively.
[0061] Blood creatinine was measured using an LC-MS / MS system connected to a NANO SPACE SI-2 (Shiseido) and a TSQ Quantum Ultra (Thermo Fisher Science). The mobile phase consisted of 0.1% formic acid (solvent A) and acetonitrile (solvent B), with elution using the following concentration gradient:
[0062] 0-1min; B 2%-5%, 1-3min; 5%-20%, 5.1-7min; 50%-100%, 7.1-10min; 100%.
[0063] The column used was a YMC-Pack Pro C18 150 × 2.0 mm ID (YMC). The flow rate was 0.2 mL / min, and the sample injection volume was 3 μL. The SRM conditions were: parent ion of creatinine at m / z 114, product ion at m / z 86, collision energy 11 V, T-Lens 100 V, creatinine-d 3 The parent ion was m / z 117, the product ion was m / z 89, the collision energy was 12 V, the T-Lens was 100 V, and the measurement mode was positive. The spray voltage, vaporizer temperature, and capillary temperature were 3,000 V, 350°C, and 350°C, respectively.
[0064] Figure 4 shows the results of measuring blood creatinine concentrations. Figure 5 shows the concentrations of indoxyl sulfate, hippuric acid, and p-cresyl sulfate in the blood. The results shown in Figures 3 and 4 confirm that lactoferrin suppresses the decline in renal function caused by adenine administration. We also confirmed that lactoferrin suppresses the increase in blood uremic toxins caused by adenine administration.
[0065] [Kidney histological analysis] Next, histological analysis of the kidneys was performed. <Masson trichrome staining> The kidneys removed at the time of autopsy were fixed in 4% paraformaldehyde (PFA) (168-23255; Wako Pure Chemical Industries, Ltd.), embedded in paraffin, and then sliced to 2 μm.
[0066] Masson trichrome staining was performed using a Masson-Golder staining kit (100485; Sigma-Aldrich, Co., St. Louis, MO, USA).
[0067] Kidney sections on glass slides were deparaffinized with 80% xylene and 99.5% ethanol, and then stained with hematoxylin for 5 minutes. After rinsing with tap water for 5 minutes, they were washed with 1% acetic acid (01021-00; KANTO CHEMICAL CO., INC.) for 30 seconds and then immersed in azophloxine solution for 10 minutes for reaction. They were then washed with 1% acetic acid for 30 seconds and immersed in Tungstophosphoric acid orange G solution for 1 minute. They were then washed with 1% acetic acid for 30 seconds, immersed in Light Green SF solution for 2 minutes, and then washed again with 1% acetic acid for 30 seconds. The sections were dehydrated and cleared with three baths of 80% xylene and four baths of 99.5% ethanol, and then mounted using Entellan (registered trademark) New.
[0068] <Evaluation of tubulointerstitial damage> The remaining tubule area and cortical area stained red were quantified from Masson trichrome-stained specimens using Image J. The interstitial damage of the proximal tubules was evaluated by calculating the remaining tubule percentage using the following formula. The results are shown in Figure 6.
[0069] <Evaluation of Crystal Area> 2,8-dihydroxyadenine crystals were quantified from hematoxylin eosin (HE) stained specimens using Image J. Crystal production was evaluated by calculating the area where crystals formed using the following formula. The results are shown in Figure 7.
[0070] The results shown in Figure 6 confirm that lactoferrin suppresses tubulointerstitial damage caused by adenine administration, and the results shown in Figure 7 confirm that lactoferrin suppresses crystal formation in renal tubules caused by adenine administration.
[0071] <Immunostaining> Kidneys removed at the time of autopsy were fixed in 4% paraformaldehyde (PFA) (168-23255; Wako Pure Chemical Industries, Ltd.), embedded in paraffin, and sectioned at 2 μm. Kidney sections on glass slides were deparaffinized with 80% xylene and 99.5% ethanol, washed with PBS, and then treated with proteinase K (S3020, DAKO) for 5 minutes at room temperature. After washing the slides with PBS, they were immersed in 0.3% hydrogen peroxide in methanol for 15 minutes to block endogenous peroxidase activity. After washing the slides with PBS, they were treated with Protein Block Serum-Free (X0909, DAKO) for 60 minutes at room temperature. After washing with PBS, the slides were incubated overnight at 4°C with a 200-fold diluted primary antibody, Rat anti-Mouse F4 / 80 (MCA497, SRT Bio-Rad). After washing the slides with PBS containing 0.3% Tween-20, they were incubated with a secondary antibody, Simple Stain Mouse (MAZ-PO (Rat)), for 60 minutes at room temperature. After washing the slides with PBS containing 0.3% Tween-20, they were incubated with ImmPACT DAB substrate kit (sk-4105, Vector) for 6 minutes at room temperature to develop color. After washing the slides with distilled water, nuclei were stained with hematoxylin, dehydrated with ethanol and xylene, and then cleared. The slides were then mounted.
[0072] [Evaluation of F4 / 80 Positive Rate (Regarding the Effect of Lactoferrin on the Suppression of Renal Inflammation Caused by Adenine Administration)] Specimens immunostained for F4 / 80 were photographed using a Keyence BZ-X800, and the F4 / 80-positive area was quantified using Image J. Macrophage infiltration was evaluated by calculating the F4 / 80 positive rate using the following formula. The results are shown in Figure 8.
[0073] The results shown in FIG. 8 confirm that lactoferrin has a tendency to suppress renal inflammation caused by adenine administration.
[0074] [Regarding lactoferrin's suppression of anemia caused by adenine administration] <Blood cell count> EDTA was used as a coagulant, and blood was collected from the buccal vein 3, 4, and 5 weeks after the start of the experiment. 20 μL of blood was used for blood cell count measurement. A HORIBA Microsemi LC-662 blood cell counter was used to measure blood cells. The results are shown in Figure 9. As is clear from Figure 9, it was confirmed that lactoferrin suppresses the decrease in hemoglobin and hematocrit caused by adenine administration. These results confirmed that lactoferrin suppresses anemia caused by adenine administration.
[0075] [Regarding lactoferrin's suppression of sarcopenia caused by adenine administration] <Evaluation of muscle bundle cross sections> The left thigh muscles removed at the time of autopsy were fixed in 4% paraformaldehyde (PFA) (168-23255; Wako Pure Chemical Industries, Ltd.), embedded in paraffin, sliced at 2 μm, and stained with HE. Photographs of the specimens were taken using a Keyence BZ-X800 (KEYENCE CORPORATION, Osaka, Japan). 20 muscle bundles were randomly selected from one specimen and used for analysis. Image J software was used for image analysis.
[0076] The results are shown in Figure 10. As is clear from Figure 10, it was confirmed that lactoferrin inhibited the reduction in muscle bundle cross-section caused by adenine administration.
[0077] [Lactoferrin suppresses sarcopenia caused by adenine administration] 40 to 120 mg of thigh muscle was weighed into a 2.0 mL tube (TM-625) and diluted with 0.1% formic acid in methanol (1.25 mg / mL 3-indoxyl sulfate-d 4 , 1mg / mL Creatinine-d 3 The amount of tissue to be added was calculated using the following formula: Amount added = tissue mass (g) x 1000 x 4 (μL).
[0078] Next, the tissue was disrupted using a MicroSmach MS-100 (TOMY SEIKO, Tokyo, Japan) at 5,000 rpm for 30 seconds and then sonicated for 10 minutes at room temperature. After centrifugation at 16,400 × g for 20 minutes at 4°C, 100 μL of the supernatant was transferred to a 1.5 mL tube, and 100 μL of 10 mM ammonium acetate was added and vortexed. From this, 100 μL was transferred to a 1.5 mL tube and dried under reduced pressure for 2 hours and 30 minutes to dry the sample, which was then redissolved in 10 μL of 10 mM ammonium acetate. The mixture was vortexed for 1 minute, centrifuged at 16,400 × g for 3 minutes at 4°C, and 10 μL of the mixture was placed on a 0.2 μm filter (YMC Duo-Filter, YMC, Kyoto, Japan) and centrifuged at 7,000 rpm for 3 minutes at 4°C. Five μL of 10 mM ammonium acetate was added to the filtered sample, and this sample was used to measure intramuscular uremic toxins by LC-MS / MS.
[0079] The concentrations of indoxyl sulfate and hippuric acid in the muscle are shown in Figure 11. The results shown in Figure 11 confirm that lactoferrin suppresses the accumulation of uremic toxins in the muscle caused by adenine administration.
[0080] These results confirmed that the lactoferrin group (Adenine + Lf group) suppressed the progression of chronic kidney disease complications compared with the renal failure group (Adenine group). Therefore, lactoferrin can be used to prevent chronic kidney disease complications.
[0081] [Regarding the lack of effect of lactoferrin on adenine-induced oxidative stress in the kidney] <RNA extraction and reverse transcription> Kidneys removed during mouse autopsy were flash-frozen in liquid nitrogen and stored at -80°C until RNA extraction. Kidneys were homogenized in 1.0 mL of TRI Reagent (#TR 118; Molecular Research Center, Inc., Ohio, USA), and the homogenate was transferred to a 1.5 mL tube. 200 μL of chloroform was added to the homogenate, vortexed for 20 seconds, allowed to stand at room temperature for 2-3 minutes, and then centrifuged at 12,000 × g and 4°C for 15 minutes. The upper layer (aqueous layer) was transferred to a new 1.5 mL tube, and 500 μL of 2-propanol was added. The mixture was mixed by inversion and allowed to stand at room temperature for 10 minutes. The mixture was then centrifuged at 12,000 × g and 4°C for 15 minutes, the supernatant was discarded, and 1.0 mL of 75% ethanol was added. After vortexing, the mixture was centrifuged at 7,500 × g and 4°C for 5 minutes, the supernatant was discarded, and the mixture was dried at room temperature. 50 mL of TE buffer was then added and the pellet was dissolved by tapping. The yield and purity of total RNA were determined by measuring the absorbance at 260 nm and 280 nm using a NanoDrop 2000 (Thermo Fisher Scientific, Inc.). The extracted total RNA was stored at -80°C until reverse transcription.
[0082] The reverse transcription reaction was performed using the iScript Advanced cDNA Synthesis Kit for RT-PCR (Bio-Rad) according to the instruction manual. 2.5 μg of total RNA was mixed with 2.5 μL of a premix containing iScript advanced reverse transcriptase and 5× iScript advanced reaction mix, and the mixture was diluted with sterile dH 2 The total volume was adjusted to 10 μL with 0, and the reaction was carried out in a T100 (registered trademark) Thermal cycler (Bio-Rad). The PCR program was as follows:
[0083] Step 1: 42℃ for 30min Step 2: 85℃ for 5min Step 3: 4℃ for 0min END
[0084] Table 1 shows the composition of the Premix.
[0085]
[0086] <Real-Time PCR> The cDNA solution was diluted 50-fold with MilliQ water and used for analysis. 2 μL of the cDNA solution and 10 μL of Premix were added to each well of a 96-well PCR plate (Hard-Shell 96-Well Skirted PCR Plates; Bio-Rad). Real-time PCR was performed using the CFX Connect (registered trademark) real-time PCR analysis system (Bio-Rad) with the following program:
[0087] Step1: 95℃ for 60sec Step2: 95℃ for 5sec Step3: 60℃ for 15sec Plate Read Step4: Go to Step2 39times END
[0088] Luna Universal qPCR Master Mix (BioLabs, #M3003E, Lot. 10061403), which uses a dye equivalent to SYBR Green and can be detected with a SYBR / FAM filter, was used according to the instruction manual. The composition of the premix is shown in Table 2 below, and the primers used are shown in Table 3 below. Primers were purchased from Takara Bio Inc. (the Primer Set ID in Table 3 is the model number). A calibration curve method was used for relative quantification of mRNA in organs. Actb was used as the housekeeping gene for the samples, and the expression level was expressed as a relative value, with the expression level of the control group set at 1.
[0089]
[0090]
[0091] The results are shown in Figure 12. p47phox is an important component of NADPH oxidase, and increased expression of p47phox increases oxidative stress in the kidney. The results shown in Figure 12 indicate that adenine administration increases oxidative stress in the kidney, but lactoferrin administration did not significantly suppress oxidative stress. In other words, although various experiments in this application have shown that lactoferrin suppresses the symptoms of chronic kidney disease (complications) caused by adenine administration, this means that the mechanism of action for suppressing chronic kidney disease (complications) is not the suppression of oxidative stress in the kidney.
[0092] On the other hand, Non-Patent Document 1 describes that administration of hydrogen peroxide reduces cell viability, but administration of lactoferrin improves it. In other words, Non-Patent Document 1 describes that lactoferrin inhibits hydrogen peroxide-mediated apoptosis, or in other words, lactoferrin inhibits renal damage by suppressing oxidative stress. This means that the mechanism of action of lactoferrin shown in Figure 12 and the mechanism of action of lactoferrin described in Non-Patent Document 1 are different mechanisms. In other words, it acts on damage not mediated by oxidative stress.
[0093] As described above, even when the same substance was administered, different results were obtained in the adenine-induced renal failure model mouse used in the present application and the model mouse in which folic acid-induced acute kidney injury progresses to chronic kidney disease described in Non-Patent Document 1. Therefore, it was confirmed that the mechanism of action specific to chronic kidney disease cannot be predicted from experiments using a mouse model of acute kidney injury.
[0094] [Changes in Muscle Metabolites] To investigate the metabolic changes associated with adenine and lactoferrin administration, metabolites were measured using quadriceps muscles at the time of dissection. The measurements were performed according to the following procedure.
[0095] (1) Pretreatment The weight of the left quadriceps femoris muscle of a mouse stored at -80°C was measured and homogenized in a pretreatment solution of tissue weight (g) x 1000 x 10 (μL). The composition of the pretreatment solution is as follows: 2 O: Methanol: CHCl 3Into the mixed solution with a ratio of 2:5:2, 1 / 10 of the amount of 0.5 mg / mL isopropyl malic acid (333115-100MG; ALDRICH) was dissolved as an internal standard substance.
[0096] After shaking at 1200 rpm and 37°C for 30 minutes, the mixture was centrifuged at 16,000 x g and 4°C for 3 minutes, and 200 μL of the supernatant was collected. 200 μL of ultrapure water was added, vortexed, and centrifuged at 16,000 x g and 4°C for 3 minutes, and 250 μL of the supernatant was collected. The solvent was removed using a Centrifugal Evaporator CVE-3100 (EYELA, Tokyo, Japan) or a Unitrap UT-2000 (EYELA), and the mixture was frozen at -80°C and lyophilized using a Centrifugal Evaporator CVE-1000 (EYELA) or a Freeze Dryer FDU-830 (EYELA). Eighty microliters of 20 mg / mL methoxyamine hydrochloride (#136-05933; WAKO) pyridine solution was added to the lyophilized sample, and the pellet was dissolved by vortexing and pipetting. After 20 minutes of sonication and 90 minutes of shaking at 1,200 rpm and 30°C, 40 μL of N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) (#1022-11061; GL Sciences) was added and the mixture was shaken at 1,200 rpm and 37°C for 30 minutes. After 3 minutes of centrifugation at 16,000 × g, 80 μL of the supernatant was transferred to a vial (#227-34120-01; Shimadzu) and used as the measurement sample. A 10 μL aliquot was collected from each sample to prepare a QC.
[0097] (2) Measurement The GC-MS measurement conditions are shown in Table 4. 481 metabolites were analyzed using the retention times listed in the Smart Metabolites Database (Shimadzu Co.). The results are shown as relative values, with the average of the control group set to 1.
[0098] Enrichment analysis was performed using MetaboAnalyst 5.0 based on the 104 detected metabolites. The results are shown in Figure 15. As shown in Figure 15, significant changes were observed in the degradation of valine, leucine, and isoleucine (hereinafter, these three amino acids may be collectively referred to as "BCAAs") and in the biosynthesis of BCAAs.
[0099] Figure 16 shows the results of comparing the amounts of valine, leucine, and isoleucine in the quadriceps muscle among the three groups. As is clear from Figure 16, all BCAAs were significantly reduced in the adenine group compared to the control group, and significantly increased in the adenine + LF group compared to the adenine group. From these results, it was confirmed that lactoferrin increases BCAAs in muscle.
[0100] BCAAs are amino acids closely related to skeletal muscle protein metabolism, and it is known that intracellular BCAA concentrations are reduced in CKD patients (Noel JM Cano et al., "Application of Branched-Chain Amino Acids in Human Pathological States: Renal Failure", J Nutr., 2006, Jan;136(1 Suppl):299S-307S. doi: 10.1093 / jn / 136.1.299S.). The results shown in Figure 16 suggest that lactoferrin administration has a mechanism of action that inhibits the progression of sarcopenia by suppressing the decrease in BCAAs.
[0101] [Muscle Protein Expression Analysis] To investigate the involvement of LF in the protein synthesis pathway and autophagy in muscle, protein quantification of p70S6K, phospho-p70S6K, AMPK, phospho-AMPK, LC3, β-actin, and cathepsin was performed by the following procedure.
[0102] (1) Sample Preparation 10x RIPA (9806s; Cell Signaling Technology, Inc., Danvers, USA), 100 mM PMSF (36978; Thermo Fisher Scientific, San Jose, CA, USA), Protease Inhibitor Cocktail (11836153001; Sigma-Aldrich Co., St. Louis, MO, USA), Phosphatase A 1x RIPA buffer was prepared by mixing Inhibitor (P5726; Sigma-Aldrich Co., St. Louis, MO, USA), MG-132 (M7449; Sigma-Aldrich Co., St. Louis, MO, USA), and ultrapure water. The composition of the RIPA buffer is shown in Table 5.
[0103] Mouse skeletal muscle samples were weighed and placed in 2 mL tubes. 1x RIPA buffer (prepared according to the sample weight) was added (1 mL / 100 mg sample). The tissue was disrupted on ice using a Polytron PT 1300 D (Kinematica AG, Malters, Switzerland). The tissue was then centrifuged at 14,000 x g for 10 minutes, and the supernatant was collected.
[0104] (2) Extracted Protein Quantification The extracted protein was diluted 20-fold with ultrapure water. 10 μL of BSA Standard (5000207; Bio-Rad Laboratories, Inc., Hercules, CA, USA) or a 20-fold diluted sample was added to 500 μL of Quick Start® Bradford 1xDye Reagent (500-0205; Bio-Rad Laboratories, Inc., Hercules, CA, USA) and mixed. 200 μL of the mixture was applied to a 96-well plate. Thereafter, absorbance was measured at a measurement wavelength of 595 nm using a Spectra Max 190 (Molecular Devices, Washington, D.C., USA), and a calibration curve was prepared to calculate the protein concentration of the sample.
[0105] (3) Western Blotting: 2x Laemmili Sample Buffer (161-0747; Bio-Rad Laboratories, Inc., Hercules, CA, USA) and 2-mercaptoethanol (161-6710; Bio-Rad Laboratories, Inc., Hercules, CA, USA) were mixed to prepare a loading buffer. The required amounts of sample, loading buffer, and ultrapure water were calculated based on the protein quantification results, and then mixed and heated in a heat block at 95°C for 4 minutes. For electrophoresis, a gel prepared with TGX™ FastCast® Acrylamide Kit, 12% (161-0175; Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used. Proteins were transferred to a Trans-Blot Turbo Mini Format 0.2 μm PVDF membrane (1704156; Bio-Rad Laboratories, Inc., Hercules, CA, USA). Primary antibodies diluted 1:1000 with Solution 1 (NKB-101; Toyobo, Co., Ltd., Osaka, Japan) were added and mounted, followed by shaking at 4°C overnight. The next day, the membrane was removed from the hybribag and washed with TBST-20. The membrane was then placed in a new hybribag, and a secondary antibody diluted 5000-fold with Solution 2 (NKB-101; Toyobo, Co., Ltd., Osaka, Japan) was added and sealed. The membrane was shaken at room temperature for 1 hour and then washed with TBST-20. 0.5 ml of Super Signal West Dura Extended Duration Substrate (rr34075; Thermo Fisher Scientific, San Jose, CA, USA) was applied to the membrane and incubated for 1 minute. Images were then captured using Chemi Doc MP (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The primary and secondary antibodies are listed in Table 6. Quantification of the resulting bands was performed using Image Lab 6.0.1 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).*Composition of TBST-20 TBST-20 was prepared by mixing 10x TBS (64573292; Bio-Rad): ultrapure water: Polyoxyethylene (20) Sorbitan Monolaurate (166-21213; FUJIFILM Wako Pure Chemical Corporation) in a ratio of 250:2250:2.
[0106] Figure 17 shows photographs of Western blotting of phospho-p70S6K (phosphorylated) and p70S6K (unphosphorylated) in quadriceps muscle, as well as the results of quantifying the amount of phosphorylated p70S6K relative to the expression level of unphosphorylated p70S6K by quantifying the density of the bands, and comparing the phosphorylation ratios among the three groups, with the control set at 1. Figure 18 shows photographs of Western blotting of LC3A / B and β-actin in quadriceps muscle, as well as a graph comparing the expression levels among the three groups, with the control set at 1, after correcting the expression level of LC3-II with β-actin. Figure 19 shows photographs of Western blotting of Cathepsin B and β-actin in the quadriceps muscle, and a graph comparing the expression levels among the three groups, where the expression level of LC3-II was corrected with β-actin and the quantitative value was set to Control = 1. Figure 20 shows photographs of Western blotting of phospho-AMPKα (phosphorylated) and AMPKα (non-phosphorylated) in the quadriceps muscle, and the results of quantifying the amount of phosphorylated AMPKα relative to the expression level of non-phosphorylated AMPKα by quantifying the band density, and comparing the phosphorylation rate among the three groups, where the quantitative value was set to Control = 1.
[0107] As shown in Figure 17, p70S6K phosphorylation was significantly elevated in the Adenine + LF group compared to the Control group, and tended to be elevated compared to the Adenine group. Furthermore, as shown in Figure 18, Western blotting analysis of LC3 revealed two bands, LC3-I and LC3-II. Expression of LC3-II, which is used as an autophagosome marker, increased in the Adenine group, and this increase was significantly suppressed in the Adenine + LF group. Furthermore, as shown in Figure 19, expression of Cathepsin B, a characteristic hydrolase of lysosomes, increased in the Adenine group, and this increase was significantly suppressed by LF administration.
[0108] p70S6K is a downstream protein in the mTOR signaling cascade and is known to be involved in promoting synthesis by increasing protein translation efficiency. The results shown in Figure 17 indicate that administration of lactoferrin enhanced p70S6K phosphorylation, suggesting that lactoferrin promoted muscle protein synthesis.
[0109] Autophagy is enhanced in the muscles of CKD model mice. Excessive autophagy leads to muscle atrophy. As shown in Figures 18 and 19, administration of lactoferrin is thought to suppress the expression of LC3-II and Cathepsin B, proteins that enhance autophagy, thereby suppressing muscle atrophy.
[0110] Activation of AMPK induces enhanced autophagy. While AMPKα phosphorylation increased in the adenine group, this increase was suppressed in the adenine + LF group. These results suggest that LF administration suppressed AMPKα phosphorylation by preventing the progression of the disease, thereby suppressing the increased expression of LC3-II, a marker of autophagosome formation, the early stage of autophagy, and Cathepsin B, an enzyme characteristic of lysosomal degradation. These results suggest that the suppression of autophagy-mediated protein degradation is involved in the suppression of sarcopenia progression, and that LF administration suppressed this.
[0111] [Experimental Animals and Experimental Procedures: Confirmation of the Treatment Effect on Chronic Kidney Disease Complications] Mice in a renal failure group (Adenine administration group) and a control group (Control group) were prepared using the same procedure as in the above [Experimental Animals and Experimental Procedures: Confirmation of the Preventive Effect on Chronic Kidney Disease Complications]. As is clear from the experiment in the above [Experimental Animals and Experimental Procedures: Confirmation of the Preventive Effect on Chronic Kidney Disease Complications], the renal failure group developed chronic kidney disease complications.
[0112] Next, the prepared renal failure group was randomly divided into a non-lactoferrin-administered group (referred to as "Adenine" in the figures described below) and a lactoferrin-administered group (referred to as "Adenine + Lf" in the figures described below), and fed as follows.
[0113] The renal failure group and the control group were fed the control MF diet for 4 weeks and were given tap water ad libitum.
[0114] The lactoferrin-treated group was given the control MF diet for 4 weeks, and was given a 2% lactoferrin aqueous solution ad libitum instead of tap water.
[0115] After 4 weeks, samples were collected from the mice using the same procedures as described above in [Experimental animals and experimental procedures: Confirmation of preventive effect on chronic kidney disease complications], and various analyses were performed.
[0116] [Regarding lactoferrin's treatment of renal atrophy and cardiac hypertrophy] Figure 13 shows the kidney weight corrected by body weight on the left side, and the heart weight corrected by body weight on the right side.As can be seen from Figure 13, compared with control group (Control), kidney weight is reduced and heart weight is increased in lactoferrin non-administration group (Adenine) and lactoferrin administration group (Adenine+Lf).On the other hand, compared with lactoferrin non-administration group (Adenine), kidney weight is significantly increased and heart weight is reduced in lactoferrin administration group (Adenine).In other words, it has been confirmed that administering lactoferrin to mice with renal failure improves renal atrophy and suppresses cardiac hypertrophy.
[0117] [Lactoferrin suppresses the increase of uremic toxins in blood] Compared with control group (Control), the indoxyl sulfate concentration in blood is significantly increased in lactoferrin non-administered group (Adenine) and lactoferrin administered group (Adenine+Lf).On the other hand, compared with lactoferrin non-administered group (Adenine), the indoxyl sulfate concentration in blood is significantly reduced in lactoferrin administered group (Adenine+Lf).In other words, it is confirmed that the amount of uremic toxins in blood is reduced by administering lactoferrin to mice that have renal failure.
[0118] These results suggest that the lactoferrin group (Adenine + Lf) showed a greater therapeutic effect on chronic kidney disease complications than the renal failure group (Adenine) with the same renal failure. Therefore, lactoferrin can be used to treat chronic kidney disease complications.
[0119] [Confirmation of therapeutic effect on advanced chronic kidney disease] The mice used in this experiment will be described with reference to Figure 21. In this experiment, a renal failure group (n = 12) obtained using the same procedure as the renal failure group (Adenine-administered group) mice described above in [Experimental Animals and Experimental Procedures: Confirmation of Preventive Effect on Chronic Kidney Disease Complications] was divided into two groups. One group was fed an adenine-free control MF diet for 4 weeks and was given tap water ad libitum (CKD group). The other group was fed an adenine-free control MF diet for 4 weeks and was given a 2% lactoferrin aqueous solution ad libitum instead of tap water (CKD + LF group in Figure 21). The control group was fed an adenine-free control MF diet for 10 weeks and was given tap water ad libitum.
[0120] The following experiment confirmed the effect of lactoferrin administration on CKD mice treated with adenine for six weeks. For convenience, the experiment described above in "Experimental Animals and Experimental Procedures: Confirmation of the Preventive Effect on Chronic Kidney Disease Complications" is sometimes referred to as "Example 1."
[0121] [Renal histological analysis] The experiment was carried out in the same manner as in Example 1. Figure 22 shows pathological photographs of the kidneys of each group stained with Masson trichrome, and a graph comparing the quantification of the remaining tubules among the three groups. As is clear from Figure 22, the proportion of the remaining tubule area in the cortical area was significantly reduced in the CKD group and the CKD + LF group compared to the control group, but was significantly increased in the CKD + LF group compared to the CKD group. These results confirmed that lactoferrin can treat tubulointerstitial damage caused by CKD.
[0122] [Gene Expression Analysis] Gene expression analysis of kidney fibrosis-related genes Tgfb1, Ctgf, Pai1, Col1a1, Col3a1, and Col4a1 was performed using the same procedure as in Example 1 <RNA extraction and reverse transcription>. Expression levels were normalized using Gapdh. Among the primers used, those purchased from the manufacturer (Takara Bio Inc.) are shown in Table 7 along with their model numbers. The synthesized primers are shown in Table 8 along with their sequences.
[0123]
[0124] Figure 23 shows the results of comparing the expression levels of fibrosis-related genes in the kidney among the three groups. As is clear from Figure 23, the expression of all fibrosis-related genes in the kidney, Tgfb1, Ctgf, Pai1, Col1a1, Col3a1, and Col4a1, was significantly increased in the CKD group and the CKD + LF group compared to the control group. Furthermore, compared to the CKD group, the CKD + LF group showed a tendency for Col1a1 expression to decrease, and significant decreases in Col3a1, Col4a1, Ctgf, and Pai1 expression were observed. From these results, it was confirmed that administration of lactoferrin to CKD patients reduces the expression of fibrosis-related genes, thereby exerting an anti-fibrotic effect.
[0125] [Regarding Lactoferrin's Treatment of Sarcopenia in CKD] <Evaluation of Muscle Bundle Cross Sections> An experiment was conducted using the same procedure as in <Evaluation of Muscle Bundle Cross Sections> in Example 1. Figure 24 shows a photograph of a representative cross section of an H&E-stained quadriceps muscle, a graph comparing the quantified muscle bundle cross section areas between the three groups, and a distribution diagram of the muscle bundle cross section areas. As is clear from Figure 24, it was confirmed that lactoferrin administration improves muscle atrophy associated with CKD.
[0126] <Indoxyl sulfate concentration in muscle> The concentration of indoxyl sulfate in the quadriceps femoris was examined using the same procedure as in Example 1 [Inhibition of sarcopenia caused by lactoferrin administration due to adenine administration]. Figure 25 shows the results of a comparison among the three groups. As is clear from Figure 25, it was confirmed that lactoferrin administration improved the accumulation of uremic toxins in muscle.
[0127] These results confirm that lactoferrin has a therapeutic effect on advanced chronic kidney disease.
[0128] The compositions disclosed herein can be used to treat and / or prevent complications of chronic kidney disease. Furthermore, the agents for inhibiting the progression of nephropathy, sarcopenia, and anemia can prevent or inhibit the progression of nephropathy, sarcopenia, and anemia, which are complications of chronic kidney disease. Therefore, they are useful in the medical industry.
Claims
1. A composition for use in the treatment and / or prevention of complications of chronic kidney disease, comprising lactoferrin as an active ingredient.
2. The composition according to claim 1, wherein the treatment and / or prevention of complications of chronic kidney disease is inhibition of the progression of sarcopenia and / or anemia by inhibiting the progression of renal damage in chronic kidney disease.
3. The composition according to claim 2, wherein the inhibition of progression of renal damage is inhibition of progression of at least one selected from the group consisting of renal atrophy, tubulointerstitial damage, and decreased renal function.
4. The composition according to claim 2, wherein the inhibition of progression of renal damage is inhibition of inflammation and / or fibrosis in the kidney.
5. The composition according to claim 2, wherein the inhibition of the progression of sarcopenia is an inhibition of the reduction in the cross-sectional area of muscle bundles and / or a reduction in the accumulation of uremic toxins in muscle.
6. An agent for inhibiting the progression of kidney damage in chronic kidney disease, containing lactoferrin as an active ingredient.
7. An agent for inhibiting the progression of sarcopenia in chronic kidney disease, containing lactoferrin as an active ingredient.
8. An agent for suppressing the progression of anemia in chronic kidney disease, containing lactoferrin as an active ingredient.
9. The composition according to any one of claims 1 to 5, which is used as an ingredient of a food composition or an ingredient of a pharmaceutical composition.
10. The progression inhibitor according to any one of claims 6 to 8, which is used as an ingredient of a food composition or a pharmaceutical composition.
Citation Information
Patent Citations
Pharmaceutical composition
JP2014227375A
